Childhood trauma can affect disease progression of multiple sclerosis (MS) and treatment in adulthood, a study in mice suggests. The study shows that mice that experienced early-life trauma were more likely to develop an autoimmune condition and less likely to respond to common treatment with interferon beta. The study,…
News
To potentially increase the effectiveness of COVID-19 vaccines in people with multiple sclerosis (MS), the National Multiple Sclerosis Society is recommending dosing adaptations for some disease-modifying therapies (DMTs). Based on expert consensus and available data, the guidance is particularly relevant for MS patients considering initiating or already being…
Lyfebulb and Bristol Myers Squibb have announced the 10 finalists who will compete virtually for a $25,000 award to support the development of innovations that address unmet needs in multiple sclerosis (MS). The…
The levels of KIF5A protein are elevated in the cerebrospinal fluid (CSF) — the liquid surrounding the brain and spinal cord — of people with progressive multiple sclerosis (MS) and, further, are correlated with disease progression measures in patients with relapsing-remitting MS (RRMS), a new study shows. These…
Making clinical trials more comparable, consistent, and focused on the biological mechanisms underlying the onset and development of multiple sclerosis (MS) are all key to more quickly realizing new treatments for progressive MS, according to the International Progressive MS Alliance. To attain these goals, the Alliance, a worldwide…
Greg Smiley’s world changed abruptly in 2013. He was racing down a mountain road on an outback cycling trip in South Africa, when he hit an obstruction in the road and fell face-first onto the pavement, still clipped to his bike. The impact did considerable damage, including a potentially disfiguring…
Researchers at the Kessler Foundation, with support from Genentech, are opening a study into how Ocrevus (ocrelizumab) affects cognitive fatigue — the feeling of complete exhaustion after focused concentration — in people with relapsing-remitting multiple sclerosis (RRMS). Cognitive fatigue is a frequent problem with MS, reported in…
C. Light Technologies announced it raised $2.5 million in seed funding to further develop a noninvasive eye tracking device that might diagnose multiple sclerosis (MS) and other neurological diseases through measures made in a matter of seconds. Currently a prototype, the device captures neurodegeneration by mapping what is called fixational…
The Scottish Medicines Consortium (SMC) has approved Zeposia (ozanimod) for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Zeposia is sold as a tablet, to be taken by mouth once daily. The SMC has recommended that Zeposia be prescribed for people with RRMS who experience relapses or have evidence of…
Asymptomatic damage to spinal nerves occurs even in clinically stable cases of multiple sclerosis (MS) and carries an increased risk for further lesions, a recent study suggests. Although a firm link between the asymptomatic loss of myelin in the spine and worsening disability remains to be found, this work…
Women with multiple sclerosis (MS) are not at a higher risk than those without the disease of having pregnancy complications, such as gestational diabetes, requiring an emergency cesarean section (c-section), or having a preterm or stillbirth delivery, according to the results of a new study. Yet, the study’s findings…
An estrogen-based therapy, called indazole chloride (IndCl), was shown to protect against optic nerve damage in a mouse model of multiple sclerosis (MS), a study reported. IndCl may help to improve vision in people with the disease, but…
Multiple Sclerosis Society of Canada have given CA$400,000 (about $312,500) to support a pilot clinical trial investigating the potential of metformin, a common diabetes therapy, to treat children and young adults with multiple sclerosis (MS). The Phase 1/2 feasibility trial (NCT04121468) is recruiting up to 30…
Telemedicine is a feasible and effective method of remote care for multiple sclerosis (MS) patients during the COVID-19 pandemic, an Italian study suggests. The study, “Telemedicine during the Coronavirus Disease (COVID-19) Pandemic: A Multiple Sclerosis (MS) Outpatients Service Perspective,” was published in the journal Neurology International. The…
An online auction event supporting the National Multiple Sclerosis Society is is running through Feb. 13 on Facebook. Organized by The Dyeing Arts group, the fundraising auction features tie dye and handcraft art from several online communities. The event arose from a partnership between Lighthouse Outdoor Products…
A novel medication targeting the protein folate receptor-beta (FR-beta) decreased inflammation and brain damage in a rat model of multiple sclerosis (MS). The findings were published in the Journal of Neuroinflammation, in the study “Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of…
A $2.5 million donation from the Simon Family Trust is supporting the creation of a new center of expertise to help in the development of new therapies for multiple sclerosis (MS) and other neurological diseases. The new center is being launched by researchers from Gladstone Institutes and the…
The recently launched BRAINTEASER project focuses on the use of artificial intelligence (AI) technology to improve the care of patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). An initiative of a European consortium, BRAINTEASER could benefit patients, caregivers, and clinicians by enhancing the ability to predict,…
The U.S. Food and Drug Administration (FDA) has approved an intramuscular injection formulation of Plegridy (peginterferon beta-1a) to treat people with relapsing forms of multiple sclerosis (MS). This formulation, for injection directly into muscle, is what is typically used to deliver the flu shot. According to Biogen, Plegridy’s…
Teams of scientists at the University of Toronto are sharing a nearly CA$21 million (about $16.36 million) award into research that might lead to self-repair treatments for multiple sclerosis (MS) and other neurological disorders, the university announced in a press release. Eleven teams at the university and its…
A branch of the European Medicines Agency (EMA) has recommended that Kesimpta (ofatumumab) be approved and made available to treat relapsing forms of multiple sclerosis (MS) in adults with active disease. A final decision from the European Commission (EC) is expected in about two months. Typically, the EC follows…
Long-term treatment with Tecfidera (dimethyl fumarate) safely and effectively reduces the frequency of relapses in children with relapsing-remitting multiple sclerosis (RRMS), according to 2.5 years of data from the FOCUS Phase 2 trial and its extension study. These findings are consistent with those previously reported for adult patients, supporting…
Rituximab shows long-term benefits, even among people with relapsing-remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS) who stopped its use or reduced their dose, a study reported. Researchers found little evidence of disease reactivation among patients who discontinued the medication, and an adequate inflammatory disease suppression…
Levels of neurofilament light (NfL), a protein marker of neuronal damage, appear to capture some aspects of patient‐perceived physical and functional abilities with multiple sclerosis (MS), as well as their utilization of select healthcare services, a real-world study suggests. Its researchers, however, stress that more work is needed before NfL levels…
A newly identified subset of astrocytes — cells long thought to be responsible for simply providing nutrition and support to neurons — can prevent brain inflammation by promoting the destruction of pro-inflammatory immune T-cells, scientists report. Their work also found that the anti-inflammatory activity of this astrocyte subpopulation is dependent on…
Age is a main driver of disability in multiple sclerosis (MS) and has a key influence on patients’ therapeutic responses to Tecfidera (dimethyl fumarate) and Tysabri (natalizumab), a study showed. Given those findings, age should be considered in the risk/benefit assessment that’s used in the decision-making process for…
Multiple sclerosis (MS)-associated inflammation in the cerebral cortex — the outermost layer of the brain that is involved in cognitive function — prompts the destruction of neural connections by specific immune cells, according to a study in a mouse model of MS. These immune cells targeted dendritic spines (nerve…
Innodem Neurosciences received $6 million to advance its digital biomarker eye-tracking technology as a possible way of diagnosing and monitoring neurodegenerative diseases. The technology is now being tested in people with multiple sclerosis (MS). Money raised by the Montreal-based startup came through a series A financing round led by Morningside Ventures.
People with primary progressive MS (PPMS) appeared to show a much stronger response and to be the” driving” force behind a slowing in brain atrophy seen with ibudilast treatment in the SPRINT‐MS trial, a post-hoc study analysis reports. The treatment response observed in brain atrophy was more evident…
A stem cell transplant can prevent disability progression and maintain disease remission over long periods of time in most patients with relapsing forms of multiple sclerosis (MS) who failed to respond adequately to disease-modifying therapies (DMTs), a study reports. The study, “Long-Term Clinical Outcomes of Hematopoietic…